Department of Anatomy, University of Pecs, Szigeti u 12, 7624 Pecs, Hungary.
Neuropeptides. 2012 Apr;46(2):61-70. doi: 10.1016/j.npep.2011.05.001. Epub 2011 May 31.
Pituitary adenylate cyclase activating polypeptide (PACAP) is a widespread neuropeptide with diverse effects in the nervous system and peripheral organs. One of the most well-studied effects of PACAP is its cytoprotective action, against different harmful stimuli in a wide variety of cells and tissues. PACAP occurs in the urinary system, from the kidney to the lower urinary tract. The present review focuses on the nephroprotective effects of PACAP and summarizes data obtained regarding the protective effects of PACAP in different models of kidney pathologies. In vitro data show that PACAP protects tubular cells against oxidative stress, myeloma light chain, cisplatin, cyclosporine-A and hypoxia. In vivo data provide evidence for its protective effects in ischemia/reperfusion, cisplatin, cyclosporine-A, myeloma kidney injury, diabetic nephropathy and gentamicin-induced kidney damage. Results accumulated on the renoprotective effects of PACAP suggest that PACAP is an emerging candidate for treatment of human kidney pathologies.
垂体腺苷酸环化酶激活肽（PACAP）是一种广泛存在的神经肽，在神经系统和外周器官中具有多种作用。PACAP 研究最多的作用之一是其细胞保护作用，可对抗各种细胞和组织中不同的有害刺激。PACAP 存在于泌尿系统，从肾脏到下尿路。本综述重点介绍了 PACAP 的肾保护作用，并总结了关于 PACAP 在不同肾脏病变模型中保护作用的数据。体外数据表明，PACAP 可保护肾小管细胞免受氧化应激、骨髓瘤轻链、顺铂、环孢素 A 和缺氧的损伤。体内数据为其在缺血/再灌注、顺铂、环孢素 A、骨髓瘤肾损伤、糖尿病肾病和庆大霉素诱导的肾损伤中的保护作用提供了证据。关于 PACAP 肾保护作用的研究结果表明，PACAP 是治疗人类肾脏疾病的一种有前途的候选药物。
